AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3291657 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP chemotherapy
Number of subjects: 326
Study 3291657 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (both groups)
Number of subjects: 326
Study 31189670 — intervention group
Group type: EXPERIMENTAL
Intervention: Products labelled with 0%ABV or verbal descriptors Low or Super Low
Number of subjects: 3390
Study 31189670 — intervention group
Group type: COMPARATOR
Intervention: Products labelled with higher %ABV
Number of subjects: 3390
Study 27431584 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care (n=45)
Number of subjects: 88
Study 27431584 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=43)
Number of subjects: 88
Study 27431584 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care
Number of subjects: 88
Study 27431584 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 88
Study 25380222 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized guided internet-delivered cognitive-behavioral therapy for 8 weeks
Number of subjects: 52
Study 25380222 — intervention group
Group type: COMPARATOR
Intervention: Moderated online discussion forum (control group)
Number of subjects: 52
Study 23415123 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted guidance in electronic patient record
Number of subjects: 0
Study 22018150 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicocele group
Number of subjects: 190
Study 22018150 — intervention group
Group type: COMPARATOR
Intervention: Control group (normozoospermic men, n=100)
Number of subjects: 190
Study 19614942 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg)
Number of subjects: 2478
Study 19614942 — intervention group
Group type: COMPARATOR
Intervention: Thiazolidinediones (TZD)
Number of subjects: 2478
Study 19614942 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 2478
Study 17199098 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 10
Study 17199098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 14628981 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100-400 mg once daily)
Number of subjects: 136
Study 14628981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 11042786 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecturer practitioners
Number of subjects: 117
Study 11042786 — intervention group
Group type: COMPARATOR
Intervention: University‐based senior lecturers
Number of subjects: 117
Study 9138543 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (2 micrograms x kg‐1)
Number of subjects: 60
Study 9138543 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine (0.3 mg x kg‐1)
Number of subjects: 60
Study 9138543 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 60
Study 9138543 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 8346761 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Shoe training regimen
Number of subjects: 0
Study 8346761 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometrics in a properly supervised setting
Number of subjects: 0
Study 3525615 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine treatment
Number of subjects: 17
Study 3525615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31969566 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 long‐chain fatty acids and vitamin D supplementation
Number of subjects: 695
Study 29471478 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive-Behavioral Therapy for Insomnia (iCBT-I)
Number of subjects: 255
Study 29471478 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 255
Study 28592518 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (9 mg elemental Zn/d for 4 weeks)
Number of subjects: 147
Study 28592518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 26408730 — intervention group
Group type: COMPARATOR
Intervention: 5-FU alone
Number of subjects: 855
Study 26408730 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU plus folinic acid (FA)
Number of subjects: 855
Study 26408730 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU plus interferon-alpha (IFNa)
Number of subjects: 855
Study 24187098 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-initiated multidisciplinary intervention
Number of subjects: 0
Study 24187098 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utilities Index mark 3 (HUI3)
Number of subjects: 0
Study 21440562 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS)
Number of subjects: 60
Study 21440562 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial random noise stimulation (tRNS)
Number of subjects: 60
Study 21440562 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60
Study 18241355 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electrical stimulation (E-PES)
Number of subjects: 70
Study 18241355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 16632830 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 40
Study 16632830 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 40
Study 12610815 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 12‐9566 (100 mg)
Number of subjects: 35
Study 12610815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 10593462 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced air warming
Number of subjects: 50
Study 10593462 — intervention group
Group type: COMPARATOR
Intervention: Control (no forced air warming)
Number of subjects: 50
Study 8709213 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT) monotherapy
Number of subjects: 0
Study 8709213 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT plus 2',3'-dideoxyinosine (ddI) combination therapy
Number of subjects: 0
Study 8709213 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT plus 2',3'-dideoxycytidine (ddC) combination therapy
Number of subjects: 0
Study 8709213 — intervention group
Group type: COMPARATOR
Intervention: AZT monotherapy
Number of subjects: 0
Study 8709213 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (AZT + ddI or AZT + ddC)
Number of subjects: 0
Study 1682734 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg daily
Number of subjects: 1360
Study 1682734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1360
Study 7036960 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid (hourly)
Number of subjects: 94
Study 7036960 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day)
Number of subjects: 94
Study 7036960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 30579406 — intervention group
Group type: EXPERIMENTAL
Intervention: SPOC scores at 6 weeks post-surgery
Number of subjects: 1218
Study 28488610 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 30
Study 28488610 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 30
Study 27142859 — intervention group
Group type: EXPERIMENTAL
Intervention: Competencies identified in round 1 of the survey
Number of subjects: 158
Study 27142859 — intervention group
Group type: EXPERIMENTAL
Intervention: Competencies identified in round 2 of the survey
Number of subjects: 158
Study 27142859 — intervention group
Group type: EXPERIMENTAL
Intervention: Competencies rated most important
Number of subjects: 158
Study 25127289 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive skills-building groups
Number of subjects: 152
Study 25127289 — intervention group
Group type: COMPARATOR
Intervention: Didactic psychoeducational groups
Number of subjects: 152
Study 22535269 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril +/‐ indapamide)
Number of subjects: 6105
Study 22535269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study 19433070 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpyrifos oxon (CPO) detection using a newly developed enzyme‐based assay
Number of subjects: 74
Study 19433070 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralidoxime regimen
Number of subjects: 74
Study 19433070 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcomes and response to antidotes
Number of subjects: 74
Study 18042521 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary plant sterols (2 g/day)
Number of subjects: 9
Study 18042521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 10942860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10942860 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical devices
Number of subjects: 0
Study 9506785 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (ECMO) support
Number of subjects: 6
Study 9506785 — intervention group
Group type: EXPERIMENTAL
Intervention: Uni- (LVAD) support
Number of subjects: 6
Study 9506785 — intervention group
Group type: COMPARATOR
Intervention: ECMO support
Number of subjects: 6
Study 9506785 — intervention group
Group type: COMPARATOR
Intervention: LVAD support
Number of subjects: 6
Study 8477404 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention aimed at maintaining or restoring attentional capacity
Number of subjects: 32
Study 8477404 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 32
Study 3773181 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug information sheet
Number of subjects: 71
Study 29461858 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-minute finger-tip point massage of Neiguan, Juque, and Xinshu acupoints with sticky capsaicin-dressed heat plasters
Number of subjects: 40
Study 29461858 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupressure
Number of subjects: 40
Study 27816052 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 (ω3) meal (DHA=500 mg; fish oil)
Number of subjects: 20
Study 27816052 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fat meal (16 g; coconut oil)
Number of subjects: 20
Study 27816052 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6 (ω6) meal (7.4 g; grapeseed oil)
Number of subjects: 20
Study 27816052 — intervention group
Group type: COMPARATOR
Intervention: Control meal (20% fat; olive oil)
Number of subjects: 20
Study 24739218 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical-Social Functioning (PSF)
Number of subjects: 2281
Study 24739218 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Functioning (EF)
Number of subjects: 2281
Study 24739218 — intervention group
Group type: COMPARATOR
Intervention: High Emotional Functioning (EF)
Number of subjects: 2281
Study 24739218 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of high EF trajectories
Number of subjects: 2281
Study 22519895 — intervention group
Group type: EXPERIMENTAL
Intervention: CXE closed circuit breathing system
Number of subjects: 6
Study 22519895 — intervention group
Group type: COMPARATOR
Intervention: Open circuit breathing system
Number of subjects: 6
Study 19943881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg day(-1)
Number of subjects: 90
Study 19943881 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 1 mg kg(-1) twice daily
Number of subjects: 90
Study 18179457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 354
Study 18179457 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile implants
Number of subjects: 354
Study 18179457 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 354
Study 18179457 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfied cases
Number of subjects: 354
Study 18179457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissatisfied cases
Number of subjects: 354
Study 15876898 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (n = 25)
Number of subjects: 43
Study 15876898 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 43
Study 12642046 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg on the first day, followed by 250 mg daily for 4 days)
Number of subjects: 1439
Study 12642046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1439
Study 12642046 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 1439
Study 10754944 — intervention group
Group type: EXPERIMENTAL
Intervention: Once and twice daily valaciclovir or aciclovir
Number of subjects: 1479
Study 10754944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1479
Study 8873165 — intervention group
Group type: EXPERIMENTAL
Intervention: Borg 15‐category Ratings of Perceived Exertion (RPE) scale during semirecumbent exercise
Number of subjects: 9
Study 1951212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG) 750 mg/kg administered within 72 hours of admission and every 14 days until discharge or age 3 months.
Number of subjects: 170
Study 1951212 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin) administered within 72 hours of admission and every 14 days until discharge or age 3 months.
Number of subjects: 170
Study 1951212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG)
Number of subjects: 170
Study 30236118 — intervention group
Group type: EXPERIMENTAL
Intervention: Low THC and no CBD cannabis variant
Number of subjects: 12
Study 30236118 — intervention group
Group type: EXPERIMENTAL
Intervention: Low THC and high CBD cannabis variant
Number of subjects: 12
Study 30236118 — intervention group
Group type: COMPARATOR
Intervention: High-potency cannabis (HPC)
Number of subjects: 12
Study 26547109 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg brodalumab
Number of subjects: 0
Study 26547109 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 mg brodalumab
Number of subjects: 0
Study 26547109 — intervention group
Group type: EXPERIMENTAL
Intervention: 210 mg brodalumab
Number of subjects: 0
Study 26547109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24793252 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging reminders for influenza vaccine
Number of subjects: 0
Study 24793252 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 22375571 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Resilience (TR) training program
Number of subjects: 947
Study 22375571 — intervention group
Group type: COMPARATOR
Intervention: Control group (workers in control stores)
Number of subjects: 947
Study 20195589 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol via pressurized metered-dose inhaler with spacer (50 microg/kg)
Number of subjects: 46
Study 20195589 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol via nebulization (150 microg/kg)
Number of subjects: 46
Study 20195589 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group >2 years
Number of subjects: 46
Study 20195589 — intervention group
Group type: COMPARATOR
Intervention: Age group <=2 years
Number of subjects: 46
Study 18639603 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation electrically heated cigarette smoking system (EHCSS)
Number of subjects: 60
Study 18639603 — intervention group
Group type: COMPARATOR
Intervention: Conventional cigarette (CC)
Number of subjects: 60
Study 18639603 — intervention group
Group type: COMPARATOR
Intervention: No-smoking
Number of subjects: 60
Study 16154678 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based self-instruction (VSI) program (22-min video, inflatable training manikin, audio prompting device)
Number of subjects: 285
Study 16154678 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based self-instruction (VSI) program
Number of subjects: 285
Study 16154678 — intervention group
Group type: COMPARATOR
Intervention: Heartsaver training
Number of subjects: 285
Study 16154678 — intervention group
Group type: COMPARATOR
Intervention: Untrained control group
Number of subjects: 285
Study 12927002 — intervention group
Group type: EXPERIMENTAL
Intervention: mirtazapine (15 mg daily increased to 30 mg daily after 1 week)
Number of subjects: 50
Study 12927002 — intervention group
Group type: EXPERIMENTAL
Intervention: mirtazapine
Number of subjects: 50
Study 12927002 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 11001892 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT) from matched related donor (MSD) and matched unrelated donor (MUD)
Number of subjects: 473
Study 11001892 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 473
Study 11001892 — intervention group
Group type: EXPERIMENTAL
Intervention: No human leukocyte antigen (HLA)-matched donor
Number of subjects: 473
Study 11001892 — intervention group
Group type: COMPARATOR
Intervention: With human leukocyte antigen (HLA)-matched donor
Number of subjects: 473
Study 11001892 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 473
Study 9869926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandimmun Neoral (n = 8)
Number of subjects: 16
Study 9869926 — intervention group
Group type: COMPARATOR
Intervention: Sandimmun (n = 8)
Number of subjects: 16
Study 9869926 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy persons)
Number of subjects: 16
Study 9869926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 16
Study 1900011 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA with intravenous metoprolol 15 mg acutely and then 200 mg orally daily
Number of subjects: 352
Study 1900011 — intervention group
Group type: COMPARATOR
Intervention: Placebo with no beta-blockade
Number of subjects: 352
Study 6141051 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (6.25 mg to 25 mg)
Number of subjects: 10
Study 6141051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30191722 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy for insomnia (Sleep Healthy Using The Internet)
Number of subjects: 87
Study 30191722 — intervention group
Group type: COMPARATOR
Intervention: Online sleep psychoeducation (Control)
Number of subjects: 87
Study 30191722 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy for insomnia
Number of subjects: 87
Study 30236079 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment plus I3C (arm 1)
Number of subjects: 5
Study 30236079 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment plus I3C and EGCG (arm 2)
Number of subjects: 5
Study 30236079 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment plus I3C and EGCG plus long-term platinum-taxane chemotherapy (arm 3)
Number of subjects: 5
Study 30236079 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment alone without neoadjuvant platinum-taxane chemotherapy (control arm 4)
Number of subjects: 5
Study 30236079 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment alone (control arm 5)
Number of subjects: 5
Study 27375066 — intervention group
Group type: EXPERIMENTAL
Intervention: Compass fundus automated perimetry (FAP)
Number of subjects: 120
Study 27375066 — intervention group
Group type: COMPARATOR
Intervention: Humphrey Field Analyzer (HFA)
Number of subjects: 120
Study 24836474 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji-Phycon DLT
Number of subjects: 17
Study 24836474 — intervention group
Group type: COMPARATOR
Intervention: Rusch DLT
Number of subjects: 17
Study 24836474 — intervention group
Group type: COMPARATOR
Intervention: Mallinckrodt DLT
Number of subjects: 17
Study 23575054 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented therapy
Number of subjects: 311
Study 23575054 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 311
Study 19531035 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs during nighttime sleep hours
Number of subjects: 88
Study 17659942 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5 mg/day (increased to 10 mg/day as tolerated)
Number of subjects: 38
Study 17659942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 16110045 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 16
Study 16110045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11861267 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC)
Number of subjects: 0
Study 10206320 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 35 mg day(-1)
Number of subjects: 119
Study 10206320 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 100 mg day(-1)
Number of subjects: 119
Study 10206320 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 150 mg day(-1)
Number of subjects: 119
Study 10206320 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 200 mg day(-1)
Number of subjects: 119
Study 10206320 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 100 mg day(-1) with 3-day loading for >55 years
Number of subjects: 119
Study 7599672 — intervention group
Group type: EXPERIMENTAL
Intervention: Time for a Change: A Program for Healthy Moms and Babies
Number of subjects: 0
Study 7599672 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 2243481 — intervention group
Group type: EXPERIMENTAL
Intervention: Dye red 630 nm laser
Number of subjects: 100
Study 2243481 — intervention group
Group type: COMPARATOR
Intervention: Argon green 514 nm laser
Number of subjects: 100
Study 30430 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate, 0.5 mg/kg intravenously
Number of subjects: 0
Study 31831574 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced motivational interviewing (group intervention)
Number of subjects: 1742
Study 31831574 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced motivational interviewing (individual intervention)
Number of subjects: 1742
Study 31831574 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1742